Purchase Order 75N93023P01112
Award Date 8/23/23
Potential Completion Date 11/30/23
Potential Value $35K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Piscataway, NJ 08854, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $17,209.00 on September 18, 2023, for custom gene synthesis and expression services. Performance occurs in Bethesda, Maryland. The order is firm fixed price with no small business set-aside. The ultimate completion date is December 31, 2023.</p>
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for customized DNA and monoclonal antibody production, valued at $49,653.58, on August 6, 2020. Performance is located in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of September 5, 2020.</p>
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for antibody gene synthesis and production, valued at $16,974.27, on August 26, 2020. The order was firm fixed price with an ultimate completion date of February 6, 2021. Work was performed at Genscript's facility in Piscataway, New Jersey.</p>
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. on September 3, 2022, for gene synthesis plasmid preparation services, with a firm fixed price ceiling of $48,665.65. Place of performance is Piscataway, New Jersey. The work supports the FY26 UDO Initiative and was sourced through a pre-solicitation opportunity posted August 24, 2022, with a September 2 deadline. Ultimate completion is scheduled for September 29, 2022.</p>
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for sequencing and gene synthesis services for 100 samples on March 17, 2022, with a ceiling value of $15,389.60. Work is performed in Piscataway, New Jersey. The order is firm fixed price with no set-aside designation and an ultimate completion date of March 16, 2023.</p>
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $14,756.36 on September 13, 2021, for sequencing services under the FY26 UDO Initiative. Performance is at Genscript's facility in Piscataway, New Jersey. The order carries a firm fixed price and was completed by December 31, 2021.</p>
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. valued at $14,979.75 on August 29, 2024, for monoclonal antibodies and plasmids services. The order is firm fixed price with no small business set-aside. Performance occurs in Piscataway, New Jersey. The modification de-obligates excess funds, with ultimate completion scheduled for May 18, 2026.</p>
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $249,243.54 firm fixed price purchase order to Genscript USA Inc. on August 27, 2023, for gene production and protein expression services. The contract, which was completed on August 26, 2024, encompasses gene synthesis, cloning, plasmid preparation, protein expression, and purification services to support NIAID's research initiatives. This was a sole source negotiated contract with no set-aside designation, awarded...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $32,540.94 firm fixed price purchase order contract to Genscript USA Inc., a for-profit biotechnology company, for DNA synthesis services. This sole-source award supports the Vaccine Research Center's efforts to develop vaccine and passive immunotherapy candidates, including monoclonal antibodies, for biodefense-related pathogens such as Ebola and Lassa...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases has awarded a $20,827.75 purchase order to Genscript USA Inc. to provide customized protein production using a baculovirus expression system. Performance will take place in Piscataway, New Jersey over a period of approximately three months concluding in mid-December 2023. The firm fixed price contract calls for Genscript to deliver the requested proteins without further...